PILLS Act

The PILLS Act creates tax credits to encourage domestic production of generic drugs and biosimilars in the United States. It offers a production credit of 30% (increasing to 35% for final drug production) with an additional bonus for components made with U.S. materials, phasing out after 2033. The bill also provides a separate 25% investment credit for facilities building or expanding production of these drugs, ending for construction after December 31, 2028. To qualify, manufacturers must produce drugs in the U.S., meet FDA compliance requirements, and not be foreign entities of concern. These provisions primarily affect U.S.-based pharmaceutical companies producing generic drugs and biosimilars.